Keith Murphy, our Executive Chairman directly overseeing all operations, is also CEO and Founder of Viscient Bio, Inc., and a serial entrepreneur and investor in biotech. Prior to co-founding Viscient Biosciences, Mr. Murphy founded Organovo Inc., in 2007 and took it public in 2012, leading it to become the world’s premier 3D bioprinting company. He co-invented the NovoGen MMX bioprinter platform and grew Organovo through early investments and pharma corporate partnerships to a peak valuation over $1B. Organovo successfully developed a Crohn’s disease drug candidate it sold to Eli Lilly in 2025 prior to Phase 2 studies. Prior to Organovo, Mr. Murphy spent ten years at Amgen in roles of increasing responsibility, including four years as the Global Operations Leader of denosumab, now marketed as Prolia & Xgeva ($46B+ annual sales). Prior to Amgen, he played a key role at Alkermes (NASDAQ:ALKS) in the successful development of once-monthly human growth hormone (hGH) in partnership with Genentech. He holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management. Mr. Murphy serves as co-chair of the Board of No Patient Left Behind, a national non-profit influential in drug pricing policy to achieve broad patient access in the USA.
